Preferential recognition of auto-antibodies against 4-hydroxynonenal modified DNA in the cancer patients

Mohammad Faisal1, Uzma Shahab2, Abdulrahman A Alatar1

  • 1Department of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia.

Abstract

Insights

Cancer patients show auto-antibodies against 4-hydroxynonenal (HNE)-damaged DNA. This HNE-modified DNA has unique epitopes that may trigger autoantibody production in cancer development.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Immunology

Background:

  • DNA damage, including strand breaks or base alterations, arises from metabolic processes and external factors.
  • Reactive oxygen species (ROS) and reactive carbonyls like 4-hydroxynonenal (HNE) induce DNA damage.
  • HNE, a lipid peroxidation product, is linked to mutagenesis and carcinogenesis.

Purpose of the Study:

  • To investigate the presence of autoantibodies against 4-hydroxynonenal-damaged DNA (HNE-DNA) in cancer patients.
  • To assess the binding characteristics of these autoantibodies to HNE-modified DNA.

Main Methods:

  • Calf thymus DNA was chemically modified using 4-hydroxynonenal (HNE).
  • Direct binding and competitive inhibition ELISA were employed to evaluate antibody binding.
  • Cancer patient sera were analyzed for autoantibody reactivity against native and HNE-modified DNA.

Main Results:

  • HNE modification altered DNA's spectral properties, causing hyperchromicity and reduced fluorescence.
  • Sera from cancer patients demonstrated significantly higher binding to HNE-damaged DNA compared to native DNA.
  • The study identified unique epitopes on HNE-modified DNA that elicit an autoantibody response.

Conclusions:

  • HNE-modified DNA possesses distinct epitopes that can induce autoantibody formation in cancer patients.
  • These autoantibodies may serve as potential biomarkers for cancer detection or progression.